436 related articles for article (PubMed ID: 23640996)
1. Mutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia.
Abdel-Wahab O; Levine RL
Blood; 2013 May; 121(18):3563-72. PubMed ID: 23640996
[TBL] [Abstract][Full Text] [Related]
2. Clinical implications of novel mutations in epigenetic modifiers in AML.
Abdel-Wahab O; Patel J; Levine RL
Hematol Oncol Clin North Am; 2011 Dec; 25(6):1119-33. PubMed ID: 22093580
[TBL] [Abstract][Full Text] [Related]
3. Mutations in epigenetic modifiers in acute myeloid leukemia and their clinical utility.
Hou HA; Tien HF
Expert Rev Hematol; 2016 May; 9(5):447-69. PubMed ID: 26789100
[TBL] [Abstract][Full Text] [Related]
4. Cooperating gene mutations in childhood acute myeloid leukemia with special reference on mutations of ASXL1, TET2, IDH1, IDH2, and DNMT3A.
Liang DC; Liu HC; Yang CP; Jaing TH; Hung IJ; Yeh TC; Chen SH; Hou JY; Huang YJ; Shih YS; Huang YH; Lin TH; Shih LY
Blood; 2013 Apr; 121(15):2988-95. PubMed ID: 23365461
[TBL] [Abstract][Full Text] [Related]
5. Mutations in TET2 and DNMT3A genes are associated with changes in global and gene-specific methylation in acute myeloid leukemia.
Ponciano-Gómez A; Martínez-Tovar A; Vela-Ojeda J; Olarte-Carrillo I; Centeno-Cruz F; Garrido E
Tumour Biol; 2017 Oct; 39(10):1010428317732181. PubMed ID: 28992762
[TBL] [Abstract][Full Text] [Related]
6. Role of genotype-based approach in the clinical management of adult acute myeloid leukemia with normal cytogenetics.
Cagnetta A; Adamia S; Acharya C; Patrone F; Miglino M; Nencioni A; Gobbi M; Cea M
Leuk Res; 2014 Jun; 38(6):649-59. PubMed ID: 24726781
[TBL] [Abstract][Full Text] [Related]
7. Measurable residual disease of canonical versus non-canonical DNMT3A, TET2, or ASXL1 mutations in AML at stem cell transplantation.
Jentzsch M; Grimm J; Bill M; Küpper J; Backhaus D; Brauer D; Schulz J; Franke GN; Vucinic V; Niederwieser D; Platzbecker U; Schwind S
Bone Marrow Transplant; 2021 Oct; 56(10):2610-2612. PubMed ID: 34267355
[No Abstract] [Full Text] [Related]
8. Acute myeloid leukemia with DNMT3A mutations.
Li Y; Zhu B
Leuk Lymphoma; 2014 Sep; 55(9):2002-12. PubMed ID: 24283755
[TBL] [Abstract][Full Text] [Related]
9. Molecular genetics of acute myeloid leukemia: clinical implications and opportunities for integrating genomics into clinical practice.
Abdel-Wahab O
Hematology; 2012 Apr; 17 Suppl 1():S39-42. PubMed ID: 22507776
[TBL] [Abstract][Full Text] [Related]
10. A genetic development route analysis on MDS subset carrying initial epigenetic gene mutations.
Li X; Xu F; Wu LY; Zhao YS; Guo J; He Q; Zhang Z; Chang CK; Wu D
Sci Rep; 2020 Jan; 10(1):826. PubMed ID: 31964915
[TBL] [Abstract][Full Text] [Related]
11. Clinical and biological impact of TET2 mutations and expression in younger adult AML patients treated within the EORTC/GIMEMA AML-12 clinical trial.
Aslanyan MG; Kroeze LI; Langemeijer SM; Koorenhof-Scheele TN; Massop M; van Hoogen P; Stevens-Linders E; van de Locht LT; Tönnissen E; van der Heijden A; da Silva-Coelho P; Cilloni D; Saglio G; Marie JP; Tang R; Labar B; Amadori S; Muus P; Willemze R; Marijt EW; de Witte T; van der Reijden BA; Suciu S; Jansen JH
Ann Hematol; 2014 Aug; 93(8):1401-12. PubMed ID: 24994606
[TBL] [Abstract][Full Text] [Related]
12. Role of DNMT3A, TET2, and IDH1/2 mutations in pre-leukemic stem cells in acute myeloid leukemia.
Chan SM; Majeti R
Int J Hematol; 2013 Dec; 98(6):648-57. PubMed ID: 23949914
[TBL] [Abstract][Full Text] [Related]
13. [The significance of the epigenetics modifying gene mutations in acute myeloid leukemia].
Wakita S; Yamaguchi H
Nihon Rinsho; 2014 Jun; 72(6):1026-32. PubMed ID: 25016799
[TBL] [Abstract][Full Text] [Related]
14. DNMT3A mutations in acute myeloid leukemia.
Shah MY; Licht JD
Nat Genet; 2011 Mar; 43(4):289-90. PubMed ID: 21445072
[TBL] [Abstract][Full Text] [Related]
15. High frequency of additional gene mutations in acute myeloid leukemia with MLL partial tandem duplication: DNMT3A mutation is associated with poor prognosis.
Kao HW; Liang DC; Kuo MC; Wu JH; Dunn P; Wang PN; Lin TL; Shih YS; Liang ST; Lin TH; Lai CY; Lin CH; Shih LY
Oncotarget; 2015 Oct; 6(32):33217-25. PubMed ID: 26375248
[TBL] [Abstract][Full Text] [Related]
16. DNMT3A in Leukemia.
Brunetti L; Gundry MC; Goodell MA
Cold Spring Harb Perspect Med; 2017 Feb; 7(2):. PubMed ID: 28003281
[TBL] [Abstract][Full Text] [Related]
17. Single nucleotide polymorphism array lesions, TET2, DNMT3A, ASXL1 and CBL mutations are present in systemic mastocytosis.
Traina F; Visconte V; Jankowska AM; Makishima H; O'Keefe CL; Elson P; Han Y; Hsieh FH; Sekeres MA; Mali RS; Kalaycio M; Lichtin AE; Advani AS; Duong HK; Copelan E; Kapur R; Olalla Saad ST; Maciejewski JP; Tiu RV
PLoS One; 2012; 7(8):e43090. PubMed ID: 22905207
[TBL] [Abstract][Full Text] [Related]
18. How do novel molecular genetic markers influence treatment decisions in acute myeloid leukemia?
Patel JP; Levine RL
Hematology Am Soc Hematol Educ Program; 2012; 2012():28-34. PubMed ID: 23233557
[TBL] [Abstract][Full Text] [Related]
19. [Clonal haematopoiesis: A concise review].
Danlos FX; Papo M; Micol JB
Rev Med Interne; 2019 Oct; 40(10):684-692. PubMed ID: 31126662
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical loss of 5-hydroxymethylcytosine expression in acute myeloid leukaemia: relationship to somatic gene mutations affecting epigenetic pathways.
Magotra M; Sakhdari A; Lee PJ; Tomaszewicz K; Dresser K; Hutchinson LM; Woda BA; Chen BJ
Histopathology; 2016 Dec; 69(6):1055-1065. PubMed ID: 27458708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
